Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
The addition of five new members to the CommonWell Health Alliance increases the group's representation to 70 percent of the acute care EHR market and 20 percent of the ambulatory EHR market.
The Health Information Management and Systems Society (HIMSS) is just one of many stakeholders pleased with the recent House vote to eliminate the sustainable growth rate (SGR) formula that for years has threatened to cut physician payment from Medicare. The group is especially happy about the focus on both interoperability and alignment of quality reporting, said Tom Leary, HIMSS vice president of government relations in an interview with Clinical Innovation + Technology.
New York City is set to ramp up its life sciences position through a $150 million public-private partnership and increasing research and development space by 150 percent.
The Consumer Partnership for eHealth, a group of more than 50 leading consumer, patient and labor organizations, appears to be the first group to submit public comments regarding the draft Shared Nationwide Interoperability Roadmap.
Google has been granted a patent by the U.S. patent office for its smart contact lens featuring a chip, electric circuit and sensor technology, according to multiple reports.
Phoenix Children's Hospital has received a $200,000 grant that will support the hospital's "Connected Patient Project," which provides customized patient care information on tablets.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
